Lipika Goyal

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 27

Top Topics

Tyrosine Kinase

Liver Metastases

Top Venues

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Fen Saj, Yue Linda Wu, Shubham Pant, Lipika Goyal
Dual checkpoint inhibition in gallbladder cancer: Bridging new hope with the need for biomarkers. Cancer 130 (17) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, an Irreversible FGFR1-4 Inhibitor: Pooled Safety analysis of 469 patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Fen Saj, Yue Linda Wu, Shubham Pant, Lipika Goyal
Dual checkpoint inhibition in gallbladder cancer: Bridging new hope with the need for biomarkers. Cancer (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine 30 (6) (2024)
Petros D Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal, James J Harding, Elizabeth C Dees, Rastislav Bahleda, Nilofer S Azad, Asha Karippot, Razelle Kurzrock, Josep Tabernero, Juha Kononen, Matthew Chau Hsien Ng, Rutika Mehta, Nataliya V Uboha, Frédéric Bigot, Valentina Boni, Samantha E Bowyer, Valeriy Breder, Andres Cervantes, Nancy Chan, James M Cleary, Mallika Dhawan, Rikke Helene Løvendahl Eefsen, James Ewing, Donna M Graham, Tormod Kyrre Guren, Jin Won Kim, Krassimir Koynov, Do Youn Oh, Rebecca A Redman, Chia-Jui Yen, David B Spetzler, Marie-Claude Roubaudi-Fraschini, Valérie Nicolas, Rafik Ait-Sarkouh, Claudio Zanna, Abdallah Ennaji, Anna Pokorska-Bocci, Keith T Flaherty
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Haley Ellis, Lipika Goyal
Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology? JCO precision oncology 8 (2024)
Haley Ellis, Lipika Goyal
Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology? JCO precision oncology 8 (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Jordi Rodon Ahnert, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nature medicine (2024)
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Toure, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, Brandi M Hudson, Damian J Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A Sharon, Lipika Goyal, Alison M Schram, Suneel D Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Jessica B Casaletto
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer discovery (2023)
Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain, Kristen Spencer, Tri Minh Le, Osama E Rahma, Jordan Maurer, Jen Stanton, Karen Zhang, Anaemy Danner De Armas, Thomas T Deleon, Marc T Roth, Mary Linton B Peters, Andrew X Zhu, Kylie Boyhen, Christine VanCott, Tushar Patel, Lewis Rowland Roberts, Stacie Lindsey, Nora Horick, Jochen K Lennerz, A John Iafrate, Laura Williams Goff, Kabir Mody, Mitesh J Borad, Rachna T Shroff, Milind M Javle, Robin Kate Kelley, Lipika Goyal
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO precision oncology 7 (2023)
Thomas Benjamin Karasic, Jennifer R Eads, Lipika Goyal
Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials. JCO precision oncology 7 (2023)
Vishwajith Sridharan, Vikram Deshpande, Abhijit Chougule, Islam Baiev, Stephanie Reyes, Emily G Barr Fritcher, Jochen K Lennerz, William R Sukov, Benjamin R Kipp, David Tsai Ting, Vikram Deshpande, Lipika Goyal
FGFR mRNA Expression in Cholangiocarcinoma and its Correlation with FGFR2 Fusion Status and Immune Signatures. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ioannis A Ziogas, Alexandros P Evangeliou, Dimitrios Giannis, Muhammad Hashim Hayat, Konstantinos S Mylonas, Samer Tohme, David A Geller, Nahel Elias, Lipika Goyal, Georgios Tsoulfas
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. The oncologist 26 (6) (2021)
Shalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, Saeed Sadeghi, Ivan Borbath, Lipika Goyal, Allen Cohn, Angela Lamarca, Do Youn Oh, Teresa Macarulla, Rachna T Shroff, Michael F Howland, Ai Li, Terry Cho, Amit Pande, Milind M Javle
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future oncology (London, England) 16 (30) (2020)